Scar

Orphan designation: Tranilast Prevention of scarring post glaucoma filtration surgery, 27/07/2010 Positive

Retrieved on: 
Thursday, April 18, 2024

Orphan designation: Tranilast Prevention of scarring post glaucoma filtration surgery, 27/07/2010 Positive

Key Points: 


Orphan designation: Tranilast Prevention of scarring post glaucoma filtration surgery, 27/07/2010 Positive

aTyr Pharma to Participate in April Investor Conferences

Retrieved on: 
Monday, April 1, 2024

SAN DIEGO, April 01, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the company will participate in two upcoming investor conferences scheduled to take place in April 2024.

Key Points: 
  • SAN DIEGO, April 01, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the company will participate in two upcoming investor conferences scheduled to take place in April 2024.
  • Details of the conferences appear below:
    For more information on how to register, please contact your Evercore ISI or Piper Sandler representative.
  • aTyr is a clinical stage biotechnology company leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation.
  • tRNA synthetases are ancient, essential proteins that have evolved novel domains that regulate diverse pathways extracellularly in humans.

Dr. Ron: The Pioneer of Next Level Deep Plane Face and Neck Lift

Retrieved on: 
Monday, April 8, 2024

The Next Level Deep Plane Face and Neck Lift is a revolutionary procedure that has been gaining popularity among patients seeking a more natural and long-lasting result.

Key Points: 
  • The Next Level Deep Plane Face and Neck Lift is a revolutionary procedure that has been gaining popularity among patients seeking a more natural and long-lasting result.
  • The Next Level Deep Plane Face and Neck Lift is just one of the many procedures offered by Dr. Ron at his state-of-the-art clinic.
  • Dr. Ron's Next Level Deep Plane Face and Neck Lift is a game-changer in the world of cosmetic surgery, and it is no surprise that it has been making waves in the industry.
  • For those seeking a more natural and long-lasting result, Dr. Ron's Next Level Deep Plane Face and Neck Lift is definitely worth considering.

Aditxt Signs a Definitive Agreement to Acquire Appili Therapeutics Inc., Developer of a Biodefense Vaccine Funded by the U.S. Department of Defense (DoD)

Retrieved on: 
Tuesday, April 2, 2024

The U.S. FDA's approval of LIKMEZ highlighted Appili’s capacity to identify and develop significant opportunities within the infectious disease domain.

Key Points: 
  • The U.S. FDA's approval of LIKMEZ highlighted Appili’s capacity to identify and develop significant opportunities within the infectious disease domain.
  • Appili licensed the manufacturing and commercialization rights in the U.S. and other selected territories to Saptalis Pharmaceuticals, LLC (“Saptalis”).
  • Appili, in collaboration with Saptalis, continued the product's development, ultimately achieving FDA approval in the United States.
  • With FDA approval, future revenue is expected to be derived from milestone payments and royalties from Saptalis under the license agreement.

Quthero Welcomes Dr. Omar Ibrahimi as Chief Medical Director

Retrieved on: 
Tuesday, April 2, 2024

TORONTO, April 2, 2024 /PRNewswire/ -- Quthero, a pioneering biotech company renowned for its unique Q-peptide platform technology, welcomes Omar Ibrahimi, MD, PhD, a world-renowned dermatologist, to the Quthero team as their Chief Medical Director.

Key Points: 
  • TORONTO, April 2, 2024 /PRNewswire/ -- Quthero, a pioneering biotech company renowned for its unique Q-peptide platform technology, welcomes Omar Ibrahimi, MD, PhD, a world-renowned dermatologist, to the Quthero team as their Chief Medical Director.
  • Quthero proudly announces that renowned dermatologist, Dr. Omar Ibrahimi, joins the team as Chief Medical Director.
  • Dr. Ibrahimi, a Harvard-trained, board-certified dermatologist, is the founder and medical director of the Connecticut Skin Institute with over 20 years of experience.
  • "It is a privilege and a great honor to have Dr. Ibrahimi join Quthero to lead the launch of Quthero's post-procedure products as a Chief Medical Director.

BRIJ Medical Bolsters Leadership Team: John Grotting Named Chairman, Bob Zollars and Jim Hinrichs Join Board

Retrieved on: 
Thursday, March 28, 2024

MARIETTA, Ga., March 28, 2024 /PRNewswire/ -- BRIJ Medical proudly welcomes three distinguished industry leaders to its Board of Directors: John Grotting , Bob Zollars , and Jim Hinrichs .

Key Points: 
  • MARIETTA, Ga., March 28, 2024 /PRNewswire/ -- BRIJ Medical proudly welcomes three distinguished industry leaders to its Board of Directors: John Grotting , Bob Zollars , and Jim Hinrichs .
  • John Grotting, who joins BRIJ as Chairman of the Board, brings a wealth of executive leadership experience in healthcare and technology to BRIJ Medical.
  • "We are thrilled to welcome John, Bob, and Jim to our Board of Directors," said Tim Gleeson , CEO of BRIJ Medical.
  • The appointment of Grotting, Zollars, and Hinrichs to BRIJ Medical's Board of Directors marks a major milestone in the company's strategic journey.

FDA Approves First Treatment for Patients with Liver Scarring Due to Fatty Liver Disease

Retrieved on: 
Thursday, March 14, 2024

NASH is a result of the progression of nonalcoholic fatty liver disease where liver inflammation, over time, can lead to liver scarring and liver dysfunction.

Key Points: 
  • NASH is a result of the progression of nonalcoholic fatty liver disease where liver inflammation, over time, can lead to liver scarring and liver dysfunction.
  • Rezdiffra is a partial activator of a thyroid hormone receptor; activation of this receptor by Rezdiffra in the liver reduces liver fat accumulation.
  • To enroll in the trial, patients needed to have a liver biopsy showing inflammation due to NASH with moderate or advanced liver scarring.
  • Patients should stop using Rezdiffra if they develop signs or symptoms of worsening liver function while on Rezdiffra treatment.

Surviving fishing gear entanglement isn’t enough for endangered right whales – females still don’t breed afterward

Retrieved on: 
Wednesday, March 13, 2024

On Feb. 14, the U.S. National Oceanic and Atmospheric Administration announced that the whale was #5120 in a catalog that tracks individual right whales.

Key Points: 
  • On Feb. 14, the U.S. National Oceanic and Atmospheric Administration announced that the whale was #5120 in a catalog that tracks individual right whales.
  • Further, the agency said, rope that had been deeply embedded in the whale’s tail had likely come from lobster fishing gear in Maine.
  • Entanglement in fishing gear is a deadly threat to these critically endangered animals.
  • Scientists estimate that before commercial whaling scaled up in the 18th and 19th centuries, there may have been as many as 10,000 North Atlantic right whales.
  • When whales become entangled in fishing gear, they use extra energy dragging it as they swim.

Smaller females are having fewer young

  • By 2018 there were only about 73 breeding females left, representing roughly half of all females and a sixth of the entire species.
  • Other research has shown that poor health and physical condition are making it harder for these females to even start breeding.
  • Smaller whales have fewer calves.
  • Many organizations are involved in tracking North Atlantic right whales, including government agencies, aquariums and conservation groups.
  • Even females who have previously reproduced are less likely to breed again following an entanglement event.
  • By identifying and photographing whales repeatedly over time, scientists can estimate different stages of their life, such as when females give birth.

Weakness of current regulations

  • If they are larger and enter the blubber, they are classified as moderate.
  • Our research makes it clear that such value-laden terms are potentially misleading because even minor entanglements can threaten whales’ successful reproduction.
  • In our view, these measures do not give enough weight to preventing all types of entanglements, regardless of severity.
  • And the plan closes trap fishing areas seasonally when whales are known to be present in those zones.

Coming back from the brink

  • While these estimates seem promising, females need to start and continue producing calves to increase whales’ numbers.
  • From our work, it is very clear that both lethal and sublethal impacts of entanglements are of grave concern for these whales.
  • She also is a member of the International Whaling Commission Scientific Committee.
  • Peter Corkeron consults for Public Employees for Environmental Responsibility on right whale conservation issues.
  • Rob Harcourt receives funding from the Australian Federal Government Department of Climate Change, Environment, Energy and Water for research on right whales.

Cardiol Therapeutics Completes Patient Enrollment in its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis

Retrieved on: 
Wednesday, February 21, 2024

Topline Results Expected in Q2 2024

Key Points: 
  • "Having achieved full patient enrollment, we are now positioned to announce high-level MAvERIC-Pilot clinical trial data in the second quarter of this year.
  • MAvERIC-Pilot (NCT05494788) is a Phase II open-label pilot study investigating the tolerance, safety, and effect of CardiolRx™ administered to patients with recurrent pericarditis.
  • The NRS is a validated clinical tool employed across multiple conditions with acute and chronic pain, including previous studies of recurrent pericarditis.
  • The only FDA-approved therapy for recurrent pericarditis, launched in 2021, is costly and is primarily used as a third-line intervention.

aTyr Pharma Announces Expanded Access Program (EAP) for EFZO-FIT™ Clinical Trial Participants

Retrieved on: 
Wednesday, February 21, 2024

SAN DIEGO, Feb. 21, 2024 (GLOBE NEWSWIRE) --  aTyr Pharma, Inc. (Nasdaq: LIFE) (aTyr or the Company), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced plans to initiate an Individual Patient Expanded Access Program (EAP) for its lead therapeutic candidate, efzofitimod, for patients with pulmonary sarcoidosis. The Individual Patient EAP is intended to allow access for patients who complete the Phase 3 EFZO-FIT™ study and wish to receive treatment with efzofitimod outside of the clinical trial.

Key Points: 
  • Individual Patient EAP allows access to efzofitimod for patients who complete the Phase 3 EFZO-FIT™ study in pulmonary sarcoidosis.
  • Company initiating program based on blinded EFZO-FIT™ study investigator and patient participant feedback.
  • The Individual Patient EAP is intended to allow access for patients who complete the Phase 3 EFZO-FIT™ study and wish to receive treatment with efzofitimod outside of the clinical trial.
  • “We are pleased to make efzofitimod available to patients beyond the duration of the EFZO-FIT™ clinical trial through this Individual Patient EAP,” said Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer of aTyr.